Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The risk of barotrauma associated with different types of ventilatory support is unclear in COVID-19 patients. The primary aim of this study was to evaluate the effect of the different respiratory support strategies on barotrauma occurrence; we also sought to determine the frequency of barotrauma and the clinical characteristics of the patients who experienced this complication.
Methods: This multicentre retrospective case-control study from 1 March 2020 to 28 February 2021 included COVID-19 patients who experienced barotrauma during hospital stay. They were matched with controls in a 1:1 ratio for the same admission period in the same ward of treatment. Univariable and multivariable logistic regression (OR) were performed to explore which factors were associated with barotrauma and in-hospital death.
Results: We included 200 cases and 200 controls. Invasive mechanical ventilation was used in 39.3% of patients in the barotrauma group, and in 20.1% of controls (p<0.001). Receiving non-invasive ventilation (C-PAP/PSV) instead of conventional oxygen therapy (COT) increased the risk of barotrauma (OR 5.04, 95% CI 2.30 - 11.08, p<0.001), similarly for invasive mechanical ventilation (OR 6.24, 95% CI 2.86-13.60, p<0.001). High Flow Nasal Oxygen (HFNO), compared with COT, did not significantly increase the risk of barotrauma. Barotrauma frequency occurred in 1.00% [95% CI 0.88-1.16] of patients; these were older (p=0.022) and more frequently immunosuppressed (p=0.013). Barotrauma was shown to be an independent risk for death (OR 5.32, 95% CI 2.82-10.03, p<0.001).
Conclusions: C-PAP/PSV compared with COT or HFNO increased the risk of barotrauma; otherwise HFNO did not. Barotrauma was recorded in 1.00% of patients, affecting mainly patients with more severe COVID-19 disease. Barotrauma was independently associated with mortality.
Trial Registration: this case-control study was prospectively registered in clinicaltrial.gov as NCT04897152 (on 21 May 2021).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684110 | PMC |
| http://dx.doi.org/10.1016/j.pulmoe.2022.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase.
Infect Dis Ther
September 2025
School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.
View Article and Find Full Text PDFA survey-based observational study on the prevalence and severity of dry eye symptoms in eye care professionals.
Clin Exp Optom
September 2025
Department of Vitreoretinal Diseases, Sankara Nethralaya, Chennai, India.
Clinical Relevance: Dry eye disease (DED) is associated with use of video screen based gadgets and long hours spent looking through microscopes. Use of 3D goggles to view 3D screens leads to eye strain and worsening of dry eye symptoms. It is important to identify and treat the symptoms in professions carrying a high risk of DED.
View Article and Find Full Text PDFC3 p.Asp1115Asn Variant-associated Atypical Hemolytic Uremic Syndrome with Spontaneous Remission Triggered by Influenza and COVID-19.
Intern Med
September 2025
Department of Gastroenterology and Nephrology, Tottori University Hospital, Japan.
The clinical manifestations of atypical hemolytic uremic syndrome (aHUS) vary depending on the genetic background. A 19-year-old man with the C3 p.Asp1115Asn variant experienced 2 episodes of recurrent aHUS following respiratory tract infections caused by influenza and COVID-19.
View Article and Find Full Text PDFObjectives: This study aimed to analyse the number of myocardial infarction (MI) admissions during the COVID-19 lockdown periods of 2020 and 2021 (March 15th to June 15th) and compare them with corresponding pre-pandemic period in 2019. The study also evaluated changes in critical treatment intervals: onset to door (O2D), door to balloon (D2B) and door to needle (D2N) and assessed 30-day clinical outcomes. This study examined MI care trends in India during the COVID-19 lockdown period, irrespective of patients' COVID-19 infection status.
View Article and Find Full Text PDFPediatric bronchiectasis action management plan to improve clinical outcomes: An RCT.
Chest
September 2025
Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; School of Nursing and Midwifery, Charles Darwin University, Darwin, Northern Territory, Australia.
Background: Managing bronchiectasis exacerbations is a priority for patients/parents/caregivers of children with bronchiectasis, yet evidence-based strategies among the pediatric population remain limited.
Research Question: Does the use of a personalized, written bronchiectasis action management plan (BAMP), compared to standard care, reduce non-scheduled doctor visits among children/adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis?
Study Design And Methods: Our multicenter, double-blind, superiority, randomized controlled trial enrolled children from three Australian respiratory departments between June 2018 and December 2020. Children/adolescents aged <19 years with CSLD/bronchiectasis were randomized to receive a personalized BAMP (intervention) or standard care (controls).